Citations

Clear

1011 citation(s) found for "Barry, WT".

Effects of Adeno-Associated Virus Serotype and Tissue-Specific Expression on Circulating Biomarkers of Propionic Acidemia
Guenzel, Adam J. , Hillestad, Matthew L. , Matern, Dietrich , Barry, Michael A. , Barry, Michael A

Mayo Clinic

Human Gene Therapy | July 21, 2014 | Volume: 25 | Issue: 9 | Pages: 837-843

10.1089/hum.2014.012 | PMID 25046265 Get It

Propionic acidemia (PA) is an autosomal recessive inborn error of metabolism caused by deficiency of propionyl-CoA carboxylase (PCC). This enzyme is composed of six PCCA and six PCCB subunits and mediates a critical step in catabolism of odd chain fatty acids and certain amino acids. Current treatment options for PA are limited to stringent dietary restriction of protein consumption and some patients undergo elective liver transplantation. We previously generated a hypomorphic model of PA, designated Pcca −/− (A138T), with 2% of wild-type enzyme activity that mimics many aspects of the human disease. In this study, we used the differing tissue tropisms of adeno-associated virus (AAV) to probe the ability of liver or muscle-directed gene therapy to treat systemic aspects of this disease that affects many cell types. Systemic therapy with muscle-biased AAV1, liver-biased AAV8, and broadly tropic AAVrh10 mediated significant biochemical corrections in circulating propionylcarnitine (C3) and methyl citrate by all vectors. The innate tissue bias of AAV1 and AAV8 gene expression was made more specific by the use of muscle-specific muscle creatine kinase (specifically MCK6) and hepatocyte-specific transthyretin (TTR) promoters, respectively. Under these targeted conditions, both vectors mediated significant long-term correction of circulating metabolites, demonstrating that correction of muscle and likely other tissue types in addition to liver is necessary to fully correct pathology caused by PA. Liver-specific AAV8-TTR-PCCA mediated better correction than AAV1-MCK-PCCA. These data suggest that targeted gene therapy may be a viable alternative to liver transplantation for PA. They also demonstrate the effects of tissue-specific and broad gene therapy on a cell autonomous systemic genetic disease.
Response to Letters Regarding Article, “Systemic Hypertension in Low-Gradient Severe Aortic Stenosis With Preserved Ejection Fraction”
Eleid, Mackram F. , Sorajja, Paul , Borlaug, Barry A. , Nishimura, Rick A. , Sorajja, Paul , Borlaug, Barry A

Mayo Clinic

Circulation | July 1, 2014 | Volume: 130 | Issue: 1 | Pages: No page available

10.1161/circulationaha.114.009350 | PMID 24982126 Get It

The sHunt for Better Breathing in Heart Failure With Preserved Ejection Fraction
Borlaug, Barry A. , Borlaug, Barry A

Mayo Clinic

European Journal of Heart Failure | June 11, 2014 | Volume: 16 | Issue: 7 | Pages: 709-711

10.1002/ejhf.120 | PMID 24920438 Get It

Resting Ventricular–Vascular Function and Exercise Capacity in Heart Failure With Preserved Ejection Fraction
Mohammed, Selma F. , Borlaug, Barry A. , McNulty, Steven E., Lin, Grace , Zakeri, Rosita , Semigran, Marc J., LeWinter, Martin M. , Hernandez, Adrian F. , Redfield, Margaret M. , McNulty, Steven, LeWinter, Martin, Lewis, Gregory D. , Braunwald, Eugene , Borlaug, Barry A , Hernandez, Adrian , Zakeri, Rosita

Mayo Clinic

Circulation: Heart Failure | May 16, 2014 | Volume: 7 | Issue: 4 | Pages: 580-589

10.1161/circheartfailure.114.001192 | PMID 24833648 Get It

Background— Exercise intolerance is a hallmark of heart failure, but factors associated with impaired exercise capacity in heart failure with preserved ejection fraction are unclear. We hypothesized that in heart failure with preserved ejection fraction, the severity of resting ventricular and vascular dysfunction are associated with impairment in exercise tolerance as assessed by peak oxygen consumption. Methods and Results— Subjects with heart failure with preserved ejection fraction enrolled in the PhosphodiesteRasE-5 Inhibition to Improve CLinical Status And EXercise Capacity in Diastolic Heart Failure (RELAX) clinical trial (n=216) underwent baseline Doppler echocardiography, cardiopulmonary exercise testing, and cardiac MRI. RELAX participants were elderly (median age 69 years) and 48% were women. Ejection fraction (60%) and stroke volume (77 mL) were normal, while diastolic dysfunction (medial E / e ′, 16; deceleration time, 185 ms; left atrial volume, 44 mL/m 2 ) and increased arterial load (arterial elastance, 1.51 mm Hg/mL) were evident. Peak oxygen consumption was reduced (11.7 mLkg −1 min −1 , 1141 mL/min) and age, sex, body mass index, hemoglobin, and chronotropic response collectively explained 64% of the variance in raw peak oxygen consumption (mL/min). After adjustment for these variables, left ventricular structure (diastolic dimension [1.5%, P =0.008] and left ventricular mass [1.6%, P =0.008]), resting stroke volume (2.0%, P =0.002), left ventricular diastolic dysfunction (deceleration time [0.9%, P =0.03] and E / e ′ [1.4%, P =0.009]), and arterial function (arterial elastance [2.1%, P =0.002] and systemic arterial compliance [1.5%, P =0.007]), each explained only a small additional portion of the variance in peak oxygen consumption. Conclusions— In heart failure with preserved ejection fraction, potentially modifiable factors (obesity, anemia, and chronotropic incompetence) are strongly associated with exercise capacity, whereas resting measures of ventricular and vascular structure and function are not. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00763867
Costs of Allogeneic Hematopoietic Cell Transplantation Using Reduced Intensity Conditioning Regimens
Khera, Nandita , Emmert, Amy, Storer, Barry E. , Alyea, Edwin P. , Lee, Stephanie J. , Sandmaier, Brenda M, Sandmaier, Brenda M , Lee, Stephanie J

Mayo Clinic

The Oncologist | May 6, 2014 | Volume: 19 | Issue: 6 | Pages: 639-644

10.1634/theoncologist.2013-0406 | PMID 24797822 Get It

Abstract Reduced intensity conditioning (RIC) regimens have allowed older patients and those with comorbidities to receive hematopoietic cell transplantation (HCT). We analyzed medical costs from the beginning of conditioning to 100 days after HCT for 484 patients and up to 2 years for 311 patients who underwent a RIC HCT at two institutions from January 2008 to December 2010. Multiple linear regression was used to analyze the association between clinical variables, center effect, and costs. Patient and transplant characteristics were comparable between the sites, although differences were seen in pretransplant performance scores. Significant predictors for lower costs for the first 100 days included a diagnosis of lymphoma/myeloma and use of human leukocyte antigen-matched related donors. Grade II-IV acute graft-versus-host disease (GVHD) was associated with higher costs. The overall short-term costs between the two institutions were comparable when adjusted for clinical variables (p = .43). Late costs between 100 days and 2 years after HCT were available for one cohort (n = 311); median costs during this period were $39,000 and accounted for 39% of costs during the first 2 years. Late costs were not associated with any pretransplant variables, but were higher with extensive chronic GVHD and death. After adjustment for clinical characteristics, the overall costs of the RIC transplants were similar between the two institutions despite different management approaches (inpatient vs. outpatient conditioning) and accounting methodologies. Use of unrelated/alternative donors, transplant for diseases other than lymphoma or myeloma, and acute GVHD were predictors for higher early costs, and extensive chronic GVHD and death were associated with higher late costs.
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
Jessen, Frank , Amariglio, Rebecca E. , Breteler, Monique M.B. , Ceccaldi, Mathieu , Chételat, Gaël , Dubois, Bruno , Dufouil, Carole , Ellis, Kathryn A. , Flier, Wiesje M. van der , Glodzik, Lidia , Harten, Argonde C. van , Leon, Mony J. de , McHugh, Pauline, Mielke, Michelle M. , Molinuevo, José Luís , Mosconi, Lisa , Osorio, Ricardo S. , Perrotin, Audrey , Petersen, Ronald C. , Rabin, Laura A., Rami, Lorena , Reisberg, ‌Barry , Sachdev, Perminder S. , Sayette, Vincent de La , Saykin, Andrew J. , Scheltens, Philip , Shulman, Melanie , Slavin, Melissa J., Stewart, Robert , Uspenskaya, Olga, Vellas, Bruno , Visser, Pieter Jelle , Wagner, Michael , Group, Subjective Cognitive Decline Initiative (SCD‐I) Working, Boxtel, Martin P.J. van , Rentz, Dorene M. , Sperling, Reisa Anne , Stewart, Robert , Group, Subjective Cognitive Decline Initiative (SCD‐I) Working, Mielke, Michelle M , Saykin, Andrew J , Sachdev, Perminder S , van der Flier, Wiesje M , Scheltens, Philip , Molinuevo, José Luis

Mayo Clinic

Alzheimer's & Dementia | May 3, 2014 | Volume: 10 | Issue: 6 | Pages: 844-852

10.1016/j.jalz.2014.01.001 | PMID 24798886 Get It

Abstract There is increasing evidence that subjective cognitive decline (SCD) in individuals with unimpaired performance on cognitive tests may represent the first symptomatic manifestation of Alzheimer's disease (AD). The research on SCD in early AD, however, is limited by the absence of common standards. The working group of the Subjective Cognitive Decline Initiative (SCD‐I) addressed this deficiency by reaching consensus on terminology and on a conceptual framework for research on SCD in AD. In this publication, research criteria for SCD in pre‐mild cognitive impairment (MCI) are presented. In addition, a list of core features proposed for reporting in SCD studies is provided, which will enable comparability of research across different settings. Finally, a set of features is presented, which in accordance with current knowledge, increases the likelihood of the presence of preclinical AD in individuals with SCD. This list is referred to as SCD plus .
A Randomized Pilot Study of Aortic Waveform Guided Therapy in Chronic Heart Failure
Olson, Thomas P. , Mohamed, Sahar Abdelmoneim, Melenovský, Vojtěch , Sorrell, Vincent L. , Lin, Grace , Redfield, Margaret M. , Borlaug, Barry A. , Noonan, Kelly , Melenovský, Vojtěch

Mayo Clinic

Journal of the American Heart Association | March 21, 2014 | Volume: 3 | Issue: 2 | Pages: No page available

10.1161/jaha.113.000745 | PMID 24650926 Get It

Background Medication treatment decisions in heart failure ( HF ) are currently informed by measurements of brachial artery pressure, but ventricular afterload is more accurately represented by central aortic pressure, which differs from brachial pressure. We sought to determine whether aggressive titration of vasoactive medicines beyond goal‐directed heart failure medical therapy ( GDMT ) based upon aortic pressure improves exercise capacity and cardiovascular structure‐function. Methods and Results Subjects with chronic HF (n=50) underwent cardiopulmonary exercise testing, echocardiography, and arterial tonometry to measure aortic pressure and augmentation index, and were then randomized to aortic pressure‐guided treatment (active, n=23) or conventional therapy (control, n=27). Subjects returned for 6 monthly visits wherein GDMT was first optimized. Additional vasoactive therapies were then sequentially added with the goal to reduce aortic augmentation index to 0% (active) or if brachial pressure remained elevated (control). Subjects randomized to active treatment experienced greater improvement in peak oxygen consumption compared with controls (1.37±3.76 versus −0.65±2.21 mL min −1 kg −1 , P =0.025) though reductions in aortic augmentation index were similar (−7±9% versus −5±6%, P =0.46). Forward stroke volume increased while arterial elastance and left ventricular volumes decreased in all participants, with no between‐group difference. Subjects randomized to active treatment were more likely to receive additional vasoactive therapies including nitrates, aldosterone antagonists and hydralazine, with no increased risk of hypotension or worsening renal function. Conclusions Maximization of goal‐directed medical therapy in heart failure patients may enhance afterload reduction and lead to reverse remodeling, while additional medicine titration based upon aortic pressure data improves exercise capacity in patients with heart failure.
CD46-Mediated Transduction of a Species D Adenovirus Vaccine Improves Mucosal Vaccine Efficacy
Camacho, Zenaido T., Turner, Mallory A., Barry, Michael A. , Weaver, Eric A. , Weaver, Eric A , Barry, Michael A

Mayo Clinic

Human Gene Therapy | March 18, 2014 | Volume: 25 | Issue: 4 | Pages: 364-374

10.1089/hum.2013.215 | PMID 24635714 Get It

The high levels of preexisting immunity against Adenovirus type 5 (Ad5) have deemed Ad5 unusable for translation as a human vaccine vector. Low seroprevalent alternative viral vectors may be less impacted by preexisting immunity, but they may also have significantly different phenotypes from that of Ad5. In this study we compare species D Ads (26, 28, and 48) to the species C Ad5. In vitro transduction studies show striking differences between the species C and D viruses. Most notably, Ad26 transduced human dendritic cells much more effectively than Ad5. In vivo imaging studies showed strikingly different transgene expression profiles. The Ad5 virus was superior to the species D viruses in BALB/c mice when delivered intramuscularly. However, the inverse was true when the viruses were delivered mucosally via the intranasal epithelia. Intramuscular transduction was restored in mice that ubiquitously expressed human CD46, the primary receptor for species D viruses. We analyzed both species C and D Ads for their ability to induce prophylactic immunity against influenza in the CD46 transgenic mouse model. Surprisingly, the species D vaccines again failed to induce greater levels of protective immunity as compared with the species C Ad5 when delivered intramuscularly. However, the species D Ad vaccine vector, Ad48, induced significantly greater protection as compared with Ad5 when delivered mucosally via the intranasal route in CD46 transgenic mice. These data shed light on the complexities between the species and types of Ad. Our findings indicate that more research will be required to identify the mechanisms that play a key role in the induction of protective immunity induced by species D Ad vaccines.
Reversible non‐ischaemic cardiomyopathy and left ventricular dysfunction after liver transplantation: a single‐centre experience
Yataco, Maria, Difato, Thomas, Bargehr, Johannes , Rosser, Barry G., Patel, Tushar , Trejo-Gutiérrez, Jorge F. , Pungpapong, Surakit , Aranda‐Michel, Jaime, Yataco, Maria L, Taner, C. Burcin , Patel, Tushar , Pungpapong, Surakit

Mayo Clinic

Liver International | February 17, 2014 | Volume: 34 | Issue: 6 | Pages: No page available

10.1111/liv.12501 | PMID 24529030 Get It

AbstractBackground & AimsNon‐ischaemic cardiomyopathy (NIC) is an early complication of liver transplantation (LT). Our aims were to define the prevalence, associated clinical factors, and prognosis of this condition.MethodsA retrospective study was performed on patients undergoingLTat our institution from January 2005 to December 2012. Patients who developedNICwere identified. Data collected included demographic and clinical data.ResultsA total 1460 transplants were performed in this period and seventeen patients developedNIC. Pretransplant medianQTc interval was 459 (range, 405–530), and median E/A ratio was 1 (range, 0.71–1.67). Fourteen patients (82%) were severely malnourished and required nutritional support. Thirteen patients (76%) had renal insufficiency. Median time to onset was 2 days post‐transplant (range, 0–20). Echocardiograms showed global left ventricular hypokinesis and a decrease in ejection fraction (EF) from a median of 65% (range, 50–81) pretransplant to a median of 21% (range, 15–32). Median raw model for end‐stage liver disease (MELD) score was 29 in patients withNICvs. 18 in patients without cardiomyopathy (P = 0.01). There was no significant difference between recipients withNICvs. recipients without cardiomyopathy regarding donor age, donor risk index, and cold and warm ischaemia time. Recovery of cardiac function occurred in 16 patients, with a medianEFof 44% (range, 25–65%) at the time of discharge. The last echocardiogram available showed a medianEFof 59% (range, 49–73%). One‐year survival of NIC patients was 94.1%.ConclusionNon‐ischaemic cardiomyopathy is a rare complication afterLT. Patients withNICare critically ill, with highMELDscore, and severe malnutrition.
Interatrial pressure gradients during simulated obstructive sleep apnea: A catheter‐based study
Konečný, Tomáš , Khanna, Amber , Jama, Abdi A., Zawadowski, George, Orban, Marek , Pressman, Gregg S. , Bukartyk, Jan , Kára, Tomáš, Cetta, Frank , Reeder, Guy S., Novák, Jan , Borlaug, Barry A. , Somers, Virend K. , Khanna, Amber D

Mayo Clinic

Catheterization and Cardiovascular Interventions | February 13, 2014 | Volume: 84 | Issue: 7 | Pages: 1138-1145

10.1002/ccd.25433 | PMID 24677689 Get It

ObjectivesWe set to measure the interatrial pressure gradient during simulated obstructive sleep apnea (OSA).BackgroundOSA occurs when a sleeping patient attempts to inhale against an obstructed airway. How this event affects the interatrial pressure gradient has not been defined. We hypothesized that simulated OSA in a conscious subject (Mueller maneuver [MM], inspiration against obstruction) would promote increased right‐to‐left pressure gradient, and then the substrate for right‐to‐left atrial shunting.MethodsSelected patients underwent simultaneous measurement of airway and atrial pressures (both left and right atrium [LA, RA]) using high‐fidelity micromanometry at rest, during MM, and during VM, during right heart catheterization.ResultsTen patients (age 55 ± 11 years, two women) were successfully studied. During the onset of MM, RA pressure transiently but consistently exceeded LA pressure in response to the steep decline in intrathoracic pressure (maximum RA‐LA pressure gradient increased from 0.1 ± 1.4 mm Hg at baseline to 7.0 ± 4.3 mm Hg during MM, P < 0.001). The maximum right‐to‐left atrial pressure gradient during Mueller maneuver was higher than that achieved during the Valsalva maneuver release (P < 0.007).ConclusionsThe onset of MM increased right‐to‐left pressure gradient across the atrial septum, likely as a result of greater blood return to the RA from extrathoracic veins. The RA‐LA pressure gradient achieved during MM was greater than that observed during VM. These findings delineate the hemodynamic substrate for right to left shunting during OSA. © 2014 Wiley Periodicals, Inc.